Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood 2022 Jul 07;140(1):73-77
Date
05/14/2022Pubmed ID
35560046Pubmed Central ID
PMC9262283DOI
10.1182/blood.2021014588Scopus ID
2-s2.0-85133918941 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT.
Author List
Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, Splinter NP, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan AAuthor
Demin Wang PhD Professor in the Microbiology and Immunology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, MonoclonalHumans
Immunoglobulin G
Immunologic Factors
Platelet Factor 4
Purpura, Thrombocytopenic, Idiopathic
